Companies in #Cytokine Therapeutics
Found 1 company operating in this sector.
Xencor is a clinical-stage biopharmaceutical company engineering engineered antibody and cytokine therapeutics using its XmAb and XenLock platforms. The pipeline spans XmAb819 (Phase 1, advanced clear cell renal cell carcinoma; oral presentation at ESMO 2026), plamotamab (a CD20 x CD3 bispecific in non-Hodgkin lymphoma partnered with Janssen), XmAb541 (a CLDN18.2 x 4-1BB bispecific), XmAb662 (a PD-1 x IL-15 fusion), and vudalimab (a PD-1 x CTLA-4 bispecific). The company's royalty revenues from Ultomiris (ravulizumab), Monjuvi (tafasitamab) and other partnered programs have funded an extended clinical-development runway and the 2024 strategic refocus on wholly owned oncology assets.